Search research articles
Contact Us
Filters
Showing results (181-190 of 288) with videos related to
Page
of 29
Sort By:
Investigational New Drugs
|
December 29, 2018
A phase 1 dose escalation and expansion study of Tarextumab (OMP-59R5) in patients with solid tumors
David C Smith, Rashmi Chugh, Amita Patnaik, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
May 22, 2009
Satraplatin, an oral platinum, administered on a five-day every-five-week schedule: a pharmacokinetic and food effect study
Alejandro D Ricart, John Sarantopoulos, Emiliano Calvo, et al.
British Journal of Cancer
|
April 28, 2011
Trastuzumab beyond progression in HER2-positive advanced breast cancer: the Royal Marsden experience
T Waddell, A Kotsori, A Constantinidou, et al.
Cancer Chemotherapy and Pharmacology
|
February 28, 2015
Unexpected hepatotoxicity in a phase I study of TAS266, a novel tetravalent agonistic Nanobody® targeting the DR5 receptor
Kyriakos P Papadopoulos, Randi Isaacs, Sanela Bilic, et al.
IEEE Transactions on Information Technology in Biomedicine : a Publication of the IEEE Engineering in Medicine and Biology Society
|
March 20, 2008
A national human neuroimaging collaboratory enabled by the Biomedical Informatics Research Network (BIRN)
David B Keator, J S Grethe, D Marcus, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
November 5, 2008
A phase 1 open-label, accelerated dose-escalation study of the hypoxia-activated prodrug AQ4N in patients with advanced malignancies
Kyriakos P Papadopoulos, Sanjay Goel, Murali Beeram, et al.
British Journal of Clinical Pharmacology
|
November 15, 2018
Physiologically-based pharmacokinetic modelling to predict oprozomib CYP3A drug-drug interaction potential in patients with advanced malignancies
Ying Ou, Yang Xu, Lia Gore, et al.
British Journal of Haematology
|
May 1, 1995
The fusion of TEL and ABL in human acute lymphoblastic leukaemia is a rare event
J W Janssen, S A Ridge, P Papadopoulos, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
September 17, 2014
Phase I study of 30-minute infusion of carfilzomib as single agent or in combination with low-dose dexamethasone in patients with relapsed and/or refractory multiple myeloma
Kyriakos P Papadopoulos, David S Siegel, David H Vesole, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
September 12, 2018
A First-in-Human Study of Novel Cereblon Modulator Avadomide (CC-122) in Advanced Malignancies
Drew W Rasco, Kyriakos P Papadopoulos, Michael Pourdehnad, et al.
Page
of 29
Search research articles
Search
Showing results (181-190 of 288) with videos related to
Sort By:
Page
of 29
Investigational New Drugs
|
December 29, 2018
A phase 1 dose escalation and expansion study of Tarextumab (OMP-59R5) in patients with solid tumors
David C Smith, Rashmi Chugh, Amita Patnaik, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
May 22, 2009
Satraplatin, an oral platinum, administered on a five-day every-five-week schedule: a pharmacokinetic and food effect study
Alejandro D Ricart, John Sarantopoulos, Emiliano Calvo, et al.
British Journal of Cancer
|
April 28, 2011
Trastuzumab beyond progression in HER2-positive advanced breast cancer: the Royal Marsden experience
T Waddell, A Kotsori, A Constantinidou, et al.
Cancer Chemotherapy and Pharmacology
|
February 28, 2015
Unexpected hepatotoxicity in a phase I study of TAS266, a novel tetravalent agonistic Nanobody® targeting the DR5 receptor
Kyriakos P Papadopoulos, Randi Isaacs, Sanela Bilic, et al.
IEEE Transactions on Information Technology in Biomedicine : a Publication of the IEEE Engineering in Medicine and Biology Society
|
March 20, 2008
A national human neuroimaging collaboratory enabled by the Biomedical Informatics Research Network (BIRN)
David B Keator, J S Grethe, D Marcus, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
November 5, 2008
A phase 1 open-label, accelerated dose-escalation study of the hypoxia-activated prodrug AQ4N in patients with advanced malignancies
Kyriakos P Papadopoulos, Sanjay Goel, Murali Beeram, et al.
British Journal of Clinical Pharmacology
|
November 15, 2018
Physiologically-based pharmacokinetic modelling to predict oprozomib CYP3A drug-drug interaction potential in patients with advanced malignancies
Ying Ou, Yang Xu, Lia Gore, et al.
British Journal of Haematology
|
May 1, 1995
The fusion of TEL and ABL in human acute lymphoblastic leukaemia is a rare event
J W Janssen, S A Ridge, P Papadopoulos, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
September 17, 2014
Phase I study of 30-minute infusion of carfilzomib as single agent or in combination with low-dose dexamethasone in patients with relapsed and/or refractory multiple myeloma
Kyriakos P Papadopoulos, David S Siegel, David H Vesole, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
September 12, 2018
A First-in-Human Study of Novel Cereblon Modulator Avadomide (CC-122) in Advanced Malignancies
Drew W Rasco, Kyriakos P Papadopoulos, Michael Pourdehnad, et al.
Page
of 29